Intravenous lidocaine for the treatment of acute pain in the emergency department by Fitzpatrick, Brendan Michael & Mullins, Michael Eugene




Intravenous lidocaine for the treatment of acute
pain in the emergency department
Brendan Michael Fitzpatrick
Washington University School of Medicine in St. Louis
Michael Eugene Mullins
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Fitzpatrick, Brendan Michael and Mullins, Michael Eugene, ,"Intravenous lidocaine for the treatment of acute pain in the emergency
department." Clinical and Experimental Emergency Medicine.3,2. 105-108. (2016).
http://digitalcommons.wustl.edu/open_access_pubs/5353
105Copyright © 2016 The Korean Society of Emergency Medicine
Intravenous lidocaine for the treatment 
of acute pain in the emergency 
department
Brendan Michael Fitzpatrick, Michael Eugene Mullins
Division of Emergency Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
Objective To evaluate intravenous lidocaine’s safety and efficacy as an analgesic agent in the 
treatment of a variety of painful conditions presenting to the emergency department.
Methods This case series identified seventeen patients who received lidocaine over a six month 
period and recorded demographic data, amount of lidocaine administered, the amount of opioid 
medication administered before and after lidocaine, pre- and post-lidocaine pain scores, and any 
qualitative descriptors of the patient’s pain recorded in the record. Side effects and adverse events 
were also recorded.
Results Of the seven patients who had a pre- and post-lidocaine pain score recorded, the mean 
reduction was 3 points on a 10 point scale. Patients who received lidocaine used less opioid med-
ication. One patient received an improperly high dose of lidocaine and suffered a brief seizure 
and cardiac arrest, but was quickly resuscitated.
Conclusion This series suggests that lidocaine may be a useful adjunct in the treatment of acute-
ly painful conditions in the emergency department. 
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What is already known
Intravenous lidocaine has been used to treat pain in postoperative patients, 
opioid-refractory chronic pain, and oncologic pain. Recent data suggests intra-
venous lidocaine may also be beneficial in treating acutely painful conditions in 
the emergency department.
What is new in the current study
This case series reviewed intravenous lidocaine’s effectiveness and safety in 
treating a variety of painful conditions in the emergency department, including 
but not limited to acute fracture pain, abdominal pain, sickle cell pain crisis, 
burns, contusions, and penetrating trauma. Lidocaine seemed to reduce pain 
and decreased the amount of opioids required after its administration. When 
used in appropriate doses, there were no significant side effects. This case series 
adds to the body of literature suggesting that intravenous lidocaine might be 
considered as an adjunct to acute pain management in the emergency depart-
ment across a spectrum of painful conditions.
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INTRODUCTION
Emergency physicians are familiar with lidocaine’s use as a local 
anesthetic. For many years, lidocaine was also part of the advanc-
ed cardiac life support algorithm as an anti-arrhythmic,1 and is 
even still recommended in some airway texts as a neuroprotec-
tive agent used prior to airway management in patients with ele-
vated intracranial pressure.2 
 However, lidocaine’s use as an intravenous analgesic has been 
far less popular in emergency medicine than in other areas of med-
icine. Intravenous lidocaine has been used for decades in treating 
oncologic pain,3 post-surgical pain management,4 and in chronic 
opioid-refractory pain.5 More recently, trials have shown analge-
sic efficacy in the treatment of painful conditions in the emer-
gency department; particularly in the treatment of renal colic6,7 
and limb ischemia.8
 The objectives of this case series were to evaluate intravenous 
lidocaine’s safety and efficacy as an analgesic agent in the treat-
ment of a variety of acutely painful conditions presenting to a ter-
tiary urban academic emergency department.
METHODS
Patients who received intravenous lidocaine for acute pain during 
a six month period from 1 January 2012 through 1 July 2012 were 
eligible for inclusion in this series. We excluded patients who re-
ceived intravenous lidocaine for other reasons, e.g. arrhythmia, 
neuroprotection for intubation. We identified eligible patients by 
reviewing the institution’s pharmacy data during this time. The 
study was approved by the institutional review board. 
 Data recorded included the patient’s age, sex, chief complaint 
and/or diagnosis, disposition, total amount of intravenous lido-
caine received in milligrams, triage pain score, post-lidocaine pain 
score, and any qualitative descriptors used by the patients to de-
scribe their pain before and after lidocaine. Additionally, the amo-
unt of opioids administered before and after initial lidocaine in 
morphine equivalents, and any recorded side effects or adverse 
events from lidocaine were also documented.
RESULTS
Seventeen patients met the inclusion criteria. Seven women and 
ten men comprised the study group, with a median age of 48 years 
and an age range of 23 to 81 years. The most common diagnosis 
and cause of pain was an acute fracture in 5 patients, followed 
by sickle cell pain crisis, acute back pain, and abdominal pain, with 
2 patients each. Other diagnoses were trigeminal neuralgia, acute 
ischemic foot, herpes gingostomatitis, foot contusion after motor 
vehicle collision, grease burn, and a gunshot wound to the hand. 
Ten of the patients were admitted, six were discharged home, and 
the patient with the ischemic foot underwent emergency surgery.
 The mean dose of total lidocaine was 148.53 mg, with a medi-
an and mode of 100, and range of 75 to 400 mg. Six of the sev-
enteen patients received two doses of lidocaine, and the other 
eleven received only one dose. Only seven patients had a pain 
score recorded before and after the administration of lidocaine. 
Two of these seven rated their pain as a 9/10, and five rated their 
pain as a 10/10 prior to the administration of lidocaine. The aver-
age pain reduction was 3 in these seven patients. One patient re-
ported no change in their 10/10 pain, and another noted an im-
provement from 10 to 5. 
 Reviewing nursing and provider descriptors of pain, several had 
patient quotations that indicated some improvement in their pain. 
Two patients were quoted as saying their pain was “better”, an-
other the pain was “easing up”, and one patient was quoted as 
saying “I feel fine”. Providers used the terms “improvement”, “much 
better”, and “better”. Two patients described their pain as aching 
both before and after lidocaine, but there was nothing recorded 
about the pain’s intensity. Three patients were documented as 
sleeping after receiving lidocaine.
 The patients who received intravenous lidocaine received a to-
tal of 19.07 mg of morphine-equivalent opioids. The mean total 
amount of opioid received prior to lidocaine was 11.1 and 8.5 mg 
after lidocaine. 
 One patient suffered a serious adverse effect from intravenous 
lidocaine. The treating physician mistakenly free-text ordered li-
docaine 100 mg and mistakenly approved when the nurse pre-
sented 100 mL of 1% lidocaine, which was 5 vials of 20 mL 1% 
lidocaine. At the end of the second vial, which was a cumulative 
dose of 400 mg of lidocaine, the patient seized. He soon became 
bradycardic, and eventually had a brief cardiac arrest. He was re-
suscitated successfully and made a full neurologic recovery. The 
dose of 400 mg is four times greater than the next largest single 
dose given, 100 mg, and exceeds the usual studied dose. Root cause 
analysis determined that the physician was unfamiliar with the 
correct dosing of lidocaine. 
DISCUSSION
Intravenous lidocaine has shown promise in treating acutely pain-
ful conditions, and in others it has shown no benefit. The purpose 
of this case series was to generate hypotheses for future areas of 
investigation. During a six-month-period, patients with fractures, 
sickle cell vasoocclusive crises, abdominal pain, neuropathic pain, 
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and even mucocutaneous ulcers were treated with intravenous 
lidocaine. The results suggest that some patients experienced less 
pain after administration of this agent. 
 Lidocaine is an aminoethylamide that acts primarily as a sodi-
um channel inhibitor, and exerts its effects as a local anesthetic 
by blocking sodium influx and halting action potential conduc-
tion. It blocks both open and inactivated sodium channels, with a 
greater effect seen at the already depolarized channels secondary 
to a greater positive resting potential. Thus, nerves that are re-
petitively stimulated such as those that are ischemic are more 
affected by lidocaine than non-stimulated nerves.9 Locally, this 
block occurs at the Aβ, Aδ, or C primary afferent nerves, and at 
high enough concentration, causes a complete neural blockade in 
both injured and uninjured nerves. Systemic lidocaine, however, 
does not completely block conduction of these fibers if they are 
healthy. Instead, its effects occur primarily at acutely injured nerves 
that have a tonic action potential discharge.10 A similar effect oc-
curs in animal models at damaged dorsal root basal ganglia, in 
which systemic lidocaine reduced sympathetic noradrenergic spro-
uting. This benefit lasted for 7 days after the cessation of lido-
caine.11
 In the emergency setting, Soleimanpour et al.6 conducted an 
open label case series of patients treated with lidocaine 1 mg/kg 
for relief of renal colic. Based upon favorable results, they con-
ducted a randomized trial comparing lidocaine 1 mg/kg to mor-
phine 0.1 mg/kg for relief of renal colic and found that lidocaine 
achieve better pain reduction in the first two hours after drug 
administration.7 Intravenous lidocaine has shown efficacy in treat-
ing limb ischemia,8 neuropathic pain, postoperative abdominal 
pain, and headache.12 However, it had no benefit in treating burns 
and radicular back pain.13,14 It would seem, then, that the role of 
intravenous lidocaine in the treatment of acute pain is unclear. 
 This case series reviewed the use of intravenous lidocaine for a 
variety of painful complaints, with varying success. Some patients 
reported significant decreased levels of pain and reduced admin-
istration of opioids. Lidocaine, when administered at doses up to 
3 mg/kg, was well-tolerated by patients. The single significant 
adverse event occurred at a dose of 3.66 mg/kg, and like any med-
ication, care must be taken to educate physicians and nurses re-
garding the appropriate dosing. 
 It may be that lidocaine will be found to be a useful adjunct in 
some conditions, and not useful in others. Similarly, it remains to 
be seen what lidocaine’s effect is when combined with other an-
algesics such as opioids and non-steroidal anti-inflammatory agents. 
This series does suggest that some patients with acutely painful 
conditions may benefit from intravenous lidocaine. 
 Limitations of this case series includes reliance on the accuracy 
and completeness of the written record. In a busy urban emer-
gency department, physician and nursing charting may not accu-
rately reflect the clinical reality. For instance, only 7 of the 17 pa-
tients had a pain score recorded both before and after the admin-
istration of lidocaine. 
 This type of review is also unable to control for bias and con-
founders, as there was no blinding of the patient, physician, or 
nurses. Cause and effect are also nearly impossible to establish, 
as the majority of patients received morphine prior to lidocaine, 
and improvement in their pain may have been due to the opioids, 
or at least a synergistic effect with the lidocaine. 
 This case series adds to the small but growing body of litera-
ture that supports lidocaine’s judicious use as part of a multi-mod-
al analgesia approach to acute pain in the emergency department. 
Future studies should continue to evaluate intravenous lidocaine’s 
role in treating a variety of painful conditions in the emergency 
setting. Acute fracture pain is one area in which lidocaine may be 
of benefit, as there is an acute injury that may be susceptible to 
its sodium blockade of injured tissue.
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